All In Biotech

Drug Trial Radar · NCT05257590

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

May 23, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
TaiRx, Inc.Industry
Sponsor type
Industry
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.

Conditions

  • Hepatocellular Carcinoma
  • Advanced Cancer

Interventions

  • Nivolumab Injection [Opdivo]Drug

    Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.

  • CVM-1118Drug

    CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)_mRECISTTime frame: 24 weeks after the last subject starts CVM-1118

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Keelung Chang Gung Memorial Hospital

    Keelung, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.